Carfilzomib is currently in Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. In non- clinical studies, carfilzomib has consistently exhibited a high level of selectivity for a single active site in the proteasome, and the reported clinical data to-date indicate the drug is well tolerated. The company's most advanced clinical trials of carfilzomib are evaluating the compound's activity among multiple myeloma patients who have failed or relapsed following prior therapy. In addition to carfilzomib, Proteolix has generated a rich pipeline, including an oral anti-cancer proteasome inhibitor as well as a selective inhibitor targeting the proteasome in the cells of the immune system.
New Board Member Announced
Proteolix is also pleased to announce that Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals, Inc., has joined its Board of Directors. Mr. Hastings brings more than 20 years of biotechnology and pharmaceutical industry experience as a senior-level executive in public and private companies. "Proteolix has made great progress in advancing its lead cancer therapeutic through clinical trials and developing an earlier stage pipeline of proteasome inhibitors," said Mr. Hastings on behalf of Proteolix's Board of Directors. "I personally look forward to working closely with the team on their continued success."
Mr. Hastings also serves on the board of directors of Cerimon Pharmaceuticals, Inc. and serves as a director of the Biotechnology Industry Organization (BIO) and BayBIO.
Proteolix, Inc. is a privately-held biopharmaceutical company,
headquartered in South San Francisco, dedicated to discovering, developing
and commercializing novel therapeutics that target protein degradation
pathways for cancer and autoimmune diseases. Proteolix's lead product,
|SOURCE Proteolix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved